Geode Capital Management LLC Purchases 17,893 Shares of Ralliant Corporation $RAL

Geode Capital Management LLC raised its position in shares of Ralliant Corporation (NYSE:RAL) by 1.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,872,647 shares of the company’s stock after purchasing an additional 17,893 shares during the quarter. Geode Capital Management LLC’s holdings in Ralliant were worth $95,357,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in RAL. Danske Bank A S bought a new stake in shares of Ralliant during the 4th quarter valued at about $25,000. V Square Quantitative Management LLC bought a new stake in shares of Ralliant during the 4th quarter valued at about $26,000. Allworth Financial LP grew its stake in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after purchasing an additional 293 shares during the period. Palisade Asset Management LLC bought a new stake in shares of Ralliant during the 3rd quarter valued at about $26,000. Finally, UMB Bank n.a. bought a new stake in shares of Ralliant during the 3rd quarter valued at about $29,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Zacks Research upgraded Ralliant from a “strong sell” rating to a “hold” rating in a research note on Monday, April 13th. TD Cowen increased their target price on shares of Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 20th. Vertical Research lowered shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price for the company. in a report on Wednesday, May 27th. Truist Financial reissued a “buy” rating and issued a $68.00 target price (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th. Finally, Oppenheimer increased their target price on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, May 13th. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $64.50.

Ralliant Stock Down 3.6%

Shares of RAL opened at $60.18 on Friday. The business’s 50 day moving average is $50.75 and its 200 day moving average is $49.20. The company has a market capitalization of $6.74 billion and a PE ratio of -5.50. Ralliant Corporation has a 12-month low of $37.27 and a 12-month high of $63.31. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73.

Ralliant (NYSE:RAL) last issued its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.08. The company had revenue of $534.60 million for the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.Ralliant’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Research analysts expect that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be paid a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is -1.83%.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.